COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Immune Response Following Seasonal Influenza Vaccination

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03163342
Recruitment Status : Completed
First Posted : May 23, 2017
Results First Posted : April 26, 2019
Last Update Posted : April 26, 2019
Optimal Health Research
Information provided by (Responsible Party):
Altimmune, Inc.

Brief Summary:
This is an open-label, single administration dose study in adult healthy male and female subjects. After qualifying for the study, subjects will receive a single intramuscular injection of the FDA approved 2016-2017 quadrivalent influenza vaccine.

Condition or disease Intervention/treatment Phase
Influenza Biological: Licensed seasonal influenza vaccine Phase 4

Detailed Description:

Subjects will be screened within 28 days prior to enrollment into the study. After qualifying for the study subjects will visit the clinical unit on Day l and will have pre-dose blood samples taken for humoral (serum) and cellular(peripheral blood mononuclear cells PBMCs) immunity testing and nasopharyngeal swabs for assessment of mucosa! immunity, and will then be given the vaccine.

Over the next 6 months, I 0-mL blood samples will be collected on Days 4, 8, 15, 29, 91 and 181 for HAI testing. Peripheral blood mononuclear cells will be collected on Day 8 to assess cellular responses. A nasopharyngeal swab will also be done on Day 29. Screening assessments will include clinical laboratory tests (hematology, chemistry, urinalysis (UA), drug and alcohol testing), vital signs, 12-lead electrocardiogram and physical examination.

Adverse events (AEs) will be monitored throughout the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open label
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Extent and Durability of Immune Response Following Seasonal Influenza Vaccination in Healthy Volunteers
Actual Study Start Date : May 8, 2017
Actual Primary Completion Date : November 21, 2017
Actual Study Completion Date : June 15, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Open label
Licensed seasonal influenza vaccine, intramuscular
Biological: Licensed seasonal influenza vaccine
20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine

Primary Outcome Measures :
  1. HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain [ Time Frame: Day 29 after vaccine ]
    To evaluate antibody response against matched influenza strain H1N1 A/California/04/2009 strain as measured by hemagglutination inhibition (HAI) following administration of a seasonal influenza vaccine.

Secondary Outcome Measures :
  1. Antibody Response to Divergent Influenza Strains [ Time Frame: Day 29 after vaccine ]
    l) antibody responses to divergent influenza strains as measured by hemagglutination inhibition (HAI) following administration of a seasonal influenza vaccine

  2. Cellular Immune Response [ Time Frame: Day 8 after vaccine ]
    To evaluate cellular immune responses to influenza as measured by PBMC ELISpot following administration of seasonal influenza vaccine

  3. Mucosal Influenza Antibody Response [ Time Frame: Day 29 after vaccine ]
    To evaluate mucosal influenza antibody responses as measured by IgA ELISA following administration of seasonal influenza vaccine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Men and women 18 to 50 years of age, inclusive
  2. Good general health status, as determined by the Investigator
  3. Adequate venous access for repeated phlebotomies
  4. Screening laboratory results within institutional normal range or Grade 1 elevation if the Investigator documents clinical insignificance. Bilirubin may be Grade 2 if associated with no1mal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and the Investigator considers the result not to be clinically significant (e.g. vigorous exercise or Gilbert's syndrome)
  5. Negative drug and alcohol screen at Screening and pre-dose on Day I
  6. For women of child bearing potential, negative pregnancy test
  7. Willingness to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex,monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, surgical sterilization (hysterectomy, or bilateral tubal ligation, salpingectomy, or oophorectomy), licensed hormonal methods, intrauterine device (IUD), or consistent use of a barrier method (e.g., condom, diaphragm) with spermicide for 28 days after the Fluzone Intramuscular Quadrivalent vaccine dose.

Exclusion Criteria:

  1. Pregnant, possibly pregnant, or lactating women
  2. Body mass index> 35.0 kg/m2
  3. Positive results for HIV, hepatitis B vims, or hepatitis C virus at Screening
  4. Asthma or other chronic lung disease that is greater than mild in severity. Specifically excluded are participants with any of the following events in the past year:

    • Daily symptoms
    • Daily use of short acting beta 2 agonists
    • Use of inhaled steroids or theophylline
    • Use of pulse systemic steroids
    • Emergency care or hospitalization related to asthma or other chronic lung disease
    • Systemic steroids for asthma exacerbation
  5. History of diabetes mellitus (gestational diabetes is allowed if treatment was not required postpartum and serum glucose is currently in the normal range)
  6. History of coronary artery disease, arrhythmia, or congestive heart failure
  7. Clinically significant ECG abnormality
  8. Poorly controlled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 95 mmHg) at Screening or pre-dose on Day I
  9. History of anaphylaxis or angioedema
  10. Known allergy to any of the ingredients in the vaccine formulation including egg allergy
  11. History of chronic rhinitis, nasal septal defect,cleft palate, nasal polyps, or other nasal abnormality that might affect vaccine administration
  12. Previous nasal surgery or nasal cauterization
  13. Any symptoms of upper respiratory infection or temperature> 38°C within 3 days before Day I
  14. Significant nasal congestion or rhinorrhea as assessed by the investigator.
  15. Known or suspected malignancy, excluding non-melanoma skin cancers and other early stage surgically excised malignancies that the Investigator considers to be exceedingly unlikely to recur
  16. Immunocompromised individuals, including those who have used corticosteroids (including intranasal steroids), alkylating drugs, antimetabolites, radiation, immune-modulating biologics, or other immunomodulating therapies within 90 days before Day 1 or those who plan use during the study period
  17. Use of statin medication within 30 days before Day I (including atorvastatin, fluvastatin,lovastatin, pravastatin, rosuvastatin, simvastatin, pitavastatin)
  18. Receipt of intranasal medications (including over-the-counter medications) within 30 days before Day 1
  19. Receipt of any IP within 30 days before Day 1
  20. Receipt of any vaccine within 30 days before Day I
  21. Receipt of intranasal vaccine within 90 days before Day I
  22. Receipt of any influenza vaccine within 6 months before Day I
  23. Any change in medication for a chronic medical condition within 30 days before Day I
  24. Past regular use or current use of intranasal illicit drugs or any regular use of illicit drugs by any other route.
  25. Use of tobacco products or electronic cigarettes within 30 days before Day l. Any other smoking products including marijuana will be excluded.
  26. Any medical, psychiatric, or social condition or any occupational or other responsibility that in the judgment of the Investigator would interfere with or serve as a contraindication to protocol adherence, assessment of safety (including immunogenicity), or a subject's ability to give informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03163342

Layout table for location information
United States, Maryland
Optimal Health Research
Rockville, Maryland, United States, 20850
Sponsors and Collaborators
Altimmune, Inc.
Optimal Health Research
Layout table for investigator information
Principal Investigator: Stephan Bart, MD Optimal Health Research
  Study Documents (Full-Text)

Documents provided by Altimmune, Inc.:
Study Protocol  [PDF] April 26, 2017
Statistical Analysis Plan  [PDF] April 4, 2019

Layout table for additonal information
Responsible Party: Altimmune, Inc. Identifier: NCT03163342    
Other Study ID Numbers: ALT-FLZ-401
First Posted: May 23, 2017    Key Record Dates
Results First Posted: April 26, 2019
Last Update Posted: April 26, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Altimmune, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases